InMode Ltd vs Revvity Inc — how do they compare? InMode Ltd trades at $15.33 (market cap $882.90M), while Revvity Inc trades at $110.35 (market cap $11.87B). The key difference: Revvity Inc is far larger — about 13.4× InMode Ltd's market cap, and Revvity Inc pays a 0.26% dividend while InMode Ltd pays none. Which is the better fit depends on your goals.
| INMD | RVTY | |
|---|---|---|
Market Cap | $882.90M | $11.87B |
Sector | Technology | Technology |
52-Week High | $16.62 | $117.75 |
52-Week Low | $12.76 | $82.26 |
Enterprise Value | $350.57M | $14.36B |
Dividend Yield | — | 0.26% |
Signals from Pluang's Aura AI — not financial advice
INMD trades at $15.36, down 0.71% on the day, with a bullish technical signal from moving averages but a neutral reading from oscillators. The company maintains strong profitability with a 77.84% gross margin and 23.27% net margin, though Q1 2026 earnings missed expectations. Recent news includes an unsolicited acquisition offer of $16.75 per share from Steel Partners and upcoming Q2 2026 results on August 5, 2026.
The stock presents a mixed outlook: attractive valuation multiples and a solid balance sheet support upside, but risks include earnings volatility, shareholder activism, and a securities fraud investigation. Analyst consensus is a $16.50 price target with a balanced buy/hold rating split, suggesting cautious optimism near-term.
RVTY trades at $106.44, down 3.37% today, but maintains a bullish technical outlook with strong analyst support. The company has consistently beaten earnings estimates for three consecutive quarters, with Q2 2026 results expected on August 4, 2026. Recent developments include AI integration partnerships and FDA clearances, supporting growth in its diagnostics and life sciences segments. Valuation metrics show a P/E of 52.96 and P/S of 4.35, reflecting premium pricing for its growth prospects.
The stock presents a balanced opportunity with analyst consensus pointing to 4.7% upside to the $111.43 price target. Strong institutional ownership and zero sell ratings indicate confidence, though high valuation multiples and negative cash flow trends pose risks. Earnings momentum from recent beats and strategic AI expansions provide catalysts, but investors should monitor margin pressures and China market exposure highlighted in recent quarters.
Trailing returns across standard periods
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →